The MAGE proteins: emerging roles in cell cycle progression, apoptosis, and neurogenetic disease

PA Barker, A Salehi - Journal of neuroscience research, 2002 - Wiley Online Library
Journal of neuroscience research, 2002Wiley Online Library
Since the identification of the first MAGE gene in 1991, the MAGE family has expanded
dramatically, and over 25 MAGE genes have now been identified in humans. The focus of
studies on the MAGE proteins has been their potential for cancer immunotherapy, as a result
of the finding that peptides derived from MAGE gene products are bound by major
histocompatibility complexes and presented on the cell surface of cancer cells. However, the
normal physiological role of MAGE proteins has remained a mystery. Recent studies are …
Abstract
Since the identification of the first MAGE gene in 1991, the MAGE family has expanded dramatically, and over 25 MAGE genes have now been identified in humans. The focus of studies on the MAGE proteins has been their potential for cancer immunotherapy, as a result of the finding that peptides derived from MAGE gene products are bound by major histocompatibility complexes and presented on the cell surface of cancer cells. However, the normal physiological role of MAGE proteins has remained a mystery. Recent studies are now beginning to provide insights into MAGE gene function. Necdin acts as a cell cycle regulatory protein and plays a key role in the pathogenesis of Prader‐Willi syndrome, a neurogenetic disorder. MAGE‐D1, identified as a binding partner for the p75 neurotrophin receptor, the apoptosis inhibitory protein XIAP, and Dlx/MSX homeodomain proteins, blocks cell cycle progression and enhances apoptosis. This review provides an overview of the human MAGE genes and proteins, summarizes recent findings on their cellular roles, and provides a baseline for future studies on this intriguing gene family. © 2002 Wiley‐Liss, Inc.
Wiley Online Library